Agile Therapeutics Receives the US FDA’s Approval for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System

 Agile Therapeutics Receives the US FDA’s Approval for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System

Agile Therapeutics Receives the US FDA’s Approval for Twirla (levonorgestrel and ethinyl estradiol) Transdermal System

Shots:

  • The US FDA has approved Agile’s non-daily, non-invasive contraceptive, Twirla for contraception in women with BMI is <30 kg/m2 and for whom a combined hormonal contraceptive is appropriate
  • The transdermal system must be applied weekly to the abdomen, buttock, or upper torso (Ex- breast) to deliver a 30mcg daily dose of ethinyl estradiol and 120mcg daily dose of levonorgestrel
  • The approval requires the company to conduct a post-marketing study to assess risks for venous thromboembolism and arterial thromboembolism in new users of the contraception compared with new users of other combined hormonal contraceptives

Click here ­to­ read full press release/ article | Ref: Agile Therapeutics | Image: Agile Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post